-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 27, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Yingli Pharmaceutical’s new drug application for the new generation of PI3Kδ inhibitor linpris tablets has been included in the proposed priority review list.
It is reported that in February 2021, Hengrui Medicine has reached a cooperation with Yingli Pharmaceutical and obtained the joint development rights and exclusive commercialization rights of the drug in the Greater China region.